New Patented Medicines Reported to PMPRB

Up to date as of October 25, 2017

Search by:

to

* Note: Drugs with Price Review Records linked from the brand name are only available from 2010 onward (records for 2011 will be populated over the next few months). Summary Reports are available for drug products reported prior to 2010.


YearCompanyBrand NameChemical NameDINTherapeutic UseDate of First SaleStatus
2016AbbvieSynagis - 100 mg/vialpalivizumab02438364Respiratory Syncytial Virus7 Nov 2016Within Guidelines
2016AbbvieSynagis - 50 mg/vialpalivizumab02438372Respiratory Syncytial Virus3 Nov 2016Within Guidelines
2016AbbvieVenclexta - 10 mg/tabletvenetoclax02458039Cancer31 Oct 2016Under Review
2016AbbvieVenclexta - 50 mg/tabletvenetoclax02458047Cancer31 Oct 2016Under Review
2016AbbvieVenclexta - 100 mg/tabletvenetoclax02458055Cancer2 Nov 2016Under Review
2016AbbvieVenclexta 10/50/100 - 1 N.A./kitvenetoclax02458063Cancer31 Oct 2016Under Review
2016AbbvieHumira - 40 mg/syringeadalimumab02458349Rheumatoid Arthritis16 Nov 2016Subject to Investigation
2016AbbvieHumira - 40 mg/penadalimumab02458357Rheumatoid Arthritis16 Nov 2016Subject to Investigation
2016Acerus Pharmaceuticals SRLNatesto - 5.5 mg/actuationtestosterone nasal gel02450550Hypogonadism6 May 2016Within Guidelines
2016Actelion Pharmaceuticals Canada Inc.Uptravi - 200 mg/tabletselexipag02451158Hypertension21 Apr 2016Within Guidelines
2016Actelion Pharmaceuticals Canada Inc.Uptravi - 400 mg/tabletselexipag02451166Hypertension21 Apr 2016Within Guidelines
2016Actelion Pharmaceuticals Canada Inc.Uptravi - 600 mg/tabletselexipag02451174Hypertension21 Apr 2016Within Guidelines
2016Actelion Pharmaceuticals Canada Inc.Uptravi - 800 mg/tabletselexipag02451182Hypertension21 Apr 2016Within Guidelines
2016Actelion Pharmaceuticals Canada Inc.Uptravi - 1000 mg/tabletselexipag02451190Hypertension21 Apr 2016Within Guidelines
2016Actelion Pharmaceuticals Canada Inc.Uptravi - 1200 mg/tabletselexipag02451204Hypertension21 Apr 2016Within Guidelines
2016Actelion Pharmaceuticals Canada Inc.Uptravi - 1400 mg/tabletselexipag02451212Hypertension21 Apr 2016Within Guidelines
2016Actelion Pharmaceuticals Canada Inc.Uptravi - 1600 mg/tabletselexipag02451220Hypertension21 Apr 2016Within Guidelines
2016Alexion Pharmaceuticals Inc.Strensiq - 18 mg/vialasfotase alfa02444615Paediatric-onset Hypophosphatasia20 Oct 2015 (Patented 21 Jun 2016)Under Review
2016Alexion Pharmaceuticals Inc.Strensiq - 80 mg/vialasfotase alfa02444658Paediatric-onset Hypophosphatasia17 Feb 2016Under Review
2016Allergan Inc.Fetzima - 80 mg/capsulelevomilnacipran02440997Antidepressant22 Apr 2016Within Guidelines
2016Allergan Inc.Fetzima - 120 mg/capsulelevomilnacipran02441004Antidepressant22 Apr 2016Within Guidelines
2016Allergan Inc.Belkyra - 10 mg/mLdeoxycholic acid02443910Submental Fat26 Jan 2016Within Guidelines
2016Amgen Canada Inc.Neupogen - 0.6 mg/mLfilgrastim02420104Cancer28 Jan 2016Does Not Trigger Investigation
2016Amgen Canada Inc.Neupogen - 0.6 mg/mLfilgrastim02420112Cancer2 Feb 2016Within Guidelines
2016Amgen Canada Inc.Blincyto - 38.5 mcg/vialblinatumomab02450283Cancer17 Mar 2016Within Guidelines
2016Amgen Canada Inc.Kyprolis - 60 mg/vialcarfilzomin02451034Cancer11 Feb 2016Within Guidelines
2016AstraZeneca Canada Inc.Bydureon - 2 mg/doseexenatide02448610Diabetes16 Feb 2016Within Guidelines
2016AstraZeneca Canada Inc.Xigduo 5/1000 - 1005 mg/tabletdapagliflozin / metformin hydrochloride02449943Diabetes8 Feb 2016Subject to Investigation
2016AstraZeneca Canada Inc.Lynparza - 50 mg/capsuleolaparib02454408Cancer16 May 2016Subject to Investigation
2016AstraZeneca Canada Inc.Xigduo 5/850 - 855 mg/tabletdapagliflozin / metformin hydrochloride02449935Diabetes9 Feb 2016Subject to Investigation
2016AstraZeneca Canada Inc.Brilinta - 60 mg/tabletticagrelor02455005Atherothrombosis13 Jun 2016Within Guidelines
2016AstraZeneca Canada Inc.Tagrisso - 40 mg/tabletosimertinib02456214Cancer19 Jul 2016Within Guidelines
2016AstraZeneca Canada Inc.Tagrisso - 80 mg/tabletosimertinib02456222Cancer19 Jul 2016Within Guidelines
2016Bayer Inc.Kovaltryantihemophilic factor (recombinant)02451441Hemophilia16 Jun 2016Within Guidelines
2016Bayer Inc.Kovaltryantihemophilic factor (recombinant)02451468Hemophilia16 Jun 2016Within Guidelines
2016Bayer Inc.Kovaltryantihemophilic factor (recombinant)02451476Hemophilia16 Jun 2016Within Guidelines
2016Bayer Inc.Kovaltryantihemophilic factor (recombinant)02451484Hemophilia16 Jun 2016Within Guidelines
2016Bayer Inc.Kovaltryantihemophilic factor (recombinant)02451492Hemophilia16 Jun 2016Within Guidelines
2016Bioverativ Canada Inc.Alprolix - 500 IU/vialcoagulatoin factor IX (recombinant)02422913Hemophilia15 Dec 2015 (Patented 9 Aug 2016)Within Guidelines
2016Bioverativ Canada Inc.Alprolix - 1000 IU/vialcoagulatoin factor IX (recombinant)02422921Hemophilia20 Jan 2016 (Patented 9 Aug 2016)Within Guidelines
2016Bioverativ Canada Inc.Alprolix - 2000 IU/vialcoagulatoin factor IX (recombinant)02422948Hemophilia15 Dec 2015 (Patented 9 Aug 2016)Within Guidelines
2016Bioverativ Canada Inc.Alprolix - 3000 IU/vialcoagulatoin factor IX (recombinant)02422956Hemophilia20 Dec 2015 (Patented 9 Aug 2016)Within Guidelines
2016Bioverativ Canada Inc.Eloctate - 3000 IU/vialAntihemophilic factor (Recombinant, B-domain deleted)02430355Hemophilia20 Jan 2016 (Patented 9 Aug 2016)Under Review
2016Bioverativ Canada Inc.Eloctate - 2000 IU/vialAntihemophilic factor (Recombinant, B-domain deleted)02430347Hemophilia20 Jan 2016 (Patented 9 Aug 2016)Under Review
2016Bioverativ Canada Inc.Eloctate - 1500 IU/vialAntihemophilic factor (Recombinant, B-domain deleted)02430339Hemophilia20 Jan 2016 (Patented 9 Aug 2016)Under Review
2016Bioverativ Canada Inc.Eloctate - 1000 IU/vialAntihemophilic factor (Recombinant, B-domain deleted)02430320Hemophilia20 Jan 2016 (Patented 9 Aug 2016)Under Review
2016Bioverativ Canada Inc.Eloctate - 750 IU/vialAntihemophilic factor (Recombinant, B-domain deleted)02430312Hemophilia20 Jan 2016 (Patented 9 Aug 2016)Under Review
2016Bioverativ Canada Inc.Eloctate - 500 IU/vialAntihemophilic factor (Recombinant, B-domain deleted)02430304Hemophilia20 Jan 2016 (Patented 9 Aug 2016)Under Review
2016Bioverativ Canada Inc.Eloctate - 250 IU/vialAntihemophilic factor (Recombinant, B-domain deleted)02430290Hemophilia20 Jan 2016 (Patented 9 Aug 2016)Under Review
2016Boehringer Ingelheim (Canada) Ltd.Synjardy 12.5/1000 - 1012.5 mg/tabletempagliflozin/meformin hydrochloride02456621Diabetes3 Aug 2016Within Guidelines
2016Boehringer Ingelheim (Canada) Ltd.Synjardy 12.5/500 - 512.5 mg/tabletempagliflozin/meformin hydrochloride02456605Diabetes3 Aug 2016Within Guidelines
2016Boehringer Ingelheim (Canada) Ltd.Synjardy 12.5/850 - 862.5 mg/tabletempagliflozin/meformin hydrochloride02456613Diabetes3 Aug 2016Within Guidelines
2016Boehringer Ingelheim (Canada) Ltd.Synjardy 5/1000 - 1005 mg/tabletempagliflozin/meformin hydrochloride02456591Diabetes3 Aug 2016Within Guidelines
2016Boehringer Ingelheim (Canada) Ltd.Synjardy 5/500 - 505 mg/tabletempagliflozin/meformin hydrochloride02456575Diabetes3 Aug 2016Within Guidelines
2016Boehringer Ingelheim (Canada) Ltd.Synjardy 5/850 - 855 mg/tabletempagliflozin/meformin hydrochloride02456583Diabetes3 Aug 2016Within Guidelines
2016Bristol-Myers Squibb Canada Co.Sunvepra - 100 mg/capsuleasunaprevir02452294Hepatitis C22 Apr 2016Within Guidelines
2016Bristol-Myers Squibb Canada Co.Evotaz - 450 mg/tabletatazanavir sulphate/ cobicistat02446731HIV11 Feb 2016Within Guidelines
2016Cipher Pharmaceuticals Inc.Beteflam - 2.25 mg/patchbetamethasone valerate02449773Psoriasis6 Apr 2016Subject to Investigation
2016Duchesnay Inc.Pregvitmultivitamins and minerals02451573Dietary Supplement6 Jul 2016Subject to Investigation
2016Duchesnay Inc.Pregvit Folic 5multivitamins and minerals02451581Dietary Supplement31 Aug 2016Within Guidelines
2016Eisai LimitedLenvima - 10 mg/daylenvatinib mesylate02450321Cancer29 Jul 2016Within Guidelines
2016Eisai LimitedLenvima 10/10 - 20 mg/daylenvatinib mesylate02450305Cancer13 Apr 2016Within Guidelines
2016Eisai LimitedLenvima 10/10/4 - 24 mg/daylenvatinib mesylate02450291Cancer13 Apr 2016Within Guidelines
2016Eisai LimitedLenvima 10/4 - 14 mg/daylenvatinib mesylate02450313Cancer13 Apr 2016Within Guidelines
2016Eli Lilly Canada Inc.Trulicity - 0.75 mg/pendulaglutide02448599Diabetes8 Jan 2016Within Guidelines
2016Eli Lilly Canada Inc.Taltz - 80 mg/mLixekizumab02455102Psoriasis11 Aug 2016Within Guidelines
2016Eli Lilly Canada Inc.Taltz - 80 mg/mLixekizumab02455110Psoriasis11 Aug 2016Within Guidelines
2016Ferring Inc.Cortiment - 9 mg/tabletbudesonide02455889Ulcerative colitis25 Jul 2016Within Guidelines
2016Galderma Canada Inc.TactuPump Forte - 70 g/pumpadapalene/ benzoyl peroxide02446235Acne4 Jan 2016Under Review
2016Gilead Sciences Inc.Genvoya 200/150/150/10 - 510 mg/tabletelvitegravir / cobicistat / emtricitabine / tefofovir alafenamide02449498HIV3 Feb 2016Subject to Investigation
2016Gilead Sciences Inc.Epclusa 400/100 - 500 mg/tabletsofosbuvir/velpatasvir02456370Hepatitis C2 Aug 2016Within Guidelines
2016Gilead Sciences Inc.Descovy 200/10 - 210 mg/tabletemtricitabine/tenofovir alafenamide02454416HIV3 Jun 2016Subject to Investigation
2016Gilead Sciences Inc.Descovy 200/25 - 225 mg/tabletemtricitabine/tenofovir alafenamide02454424HIV3 Jun 2016Subject to Investigation
2016GlaxoSmithKline Inc.Menjugate Liquidmeningococcal group C conjugate vaccine02440709Vaccine7 Oct 2015 (Patented 16 Aug 2016)Subject to Investigation
2016GlaxoSmithKline Inc.Arnuity Ellipta - 100 mcg/dosefluticasone furoate02446561Asthma26 Jan 2016Within Guidelines
2016GlaxoSmithKline Inc.Arnuity Ellipta - 200 mcg/dosefluticasone furoate02446588Asthma14 Dec 2015Within Guidelines
2016Hoffman-La Roche LimitedCotellic - 20 mg/tablet + Zelboraf – 240 mg/tabletcobimetinib02452340Cancer6 Apr 2016Subject to Investigation
2016Hoffman-La Roche LimitedRituxan SC - 120 mg/mLrituximab02457350Cancer22 Nov 2016Within Guidelines
2016Hospira Healthcare Corporation (Canada)Precedex - 4 mcg/mLdexmedetomidine hydrochloride02437147Sedation9 May 2016Within Guidelines
2016Janssen Inc.Zytiga - 500 mg/tabletabiraterone acetate02457113Cancer13 Oct 2016Does Not Trigger Investigation
2016Janssen Inc.Invega Trinza - 175 mg/syringepaliperidone palmitate02455943Schizophrenia2 Aug 2016Within Guidelines
2016Janssen Inc.Invega Trinza - 263 mg/syringepaliperidone palmitate02455986Schizophrenia2 Aug 2016Within Guidelines
2016Janssen Inc.Invega Trinza - 350 mg/syringepaliperidone palmitate02455994Schizophrenia2 Aug 2016Within Guidelines
2016Janssen Inc.Invega Trinza - 525 mg/syringepaliperidone palmitate02456001Schizophrenia2 Aug 2016Within Guidelines
2016Janssen Inc.Invokamet 150/1000 - 1150 mg/tabletcanagliflozin/metformin hydrochloride02455455Diabetes13 Jul 2016Within Guidelines
2016Janssen Inc.Invokamet 150/500 - 650 mg/tabletcanagliflozin/metformin hydrochloride02455439Diabetes13 Jul 2016Within Guidelines
2016Janssen Inc.Invokamet 150/850 - 1000 mg/tabletcanagliflozin/metformin hydrochloride02455447Diabetes13 Jul 2016Within Guidelines
2016Janssen Inc.Invokamet 50/1000 - 1050 mg/tabletcanagliflozin/metformin hydrochloride02455420Diabetes13 Jul 2016Within Guidelines
2016Janssen Inc.Invokamet 50/500 - 550 mg/tabletcanagliflozin/metformin hydrochloride02455404Diabetes13 Jul 2016Within Guidelines
2016Janssen Inc.Invokamet 50/850 - 900 mg/tabletcanagliflozin/metformin hydrochloride02455412Diabetes13 Jul 2016Within Guidelines
2016Leo Pharma Inc.Enstilar - 1 N.A./dosecalcipotriol/betamethasone02457393Psoriasis11 Nov 2016Subject to Investigation
2016Merck Canada Inc.Zerbaxa 1000/500 - 1500 mg/vialceftolozane / tazobactam02446901Antibiotic 12 Jan 2016Under Review
2016Merck Canada Inc.Brenzys - 50 mg/mLetanercept02455331Rheumatoid arthritis23 Sep 2016Within Guidelines
2016Merck Canada Inc.Brenzys - 50 mg/mLetanercept02455323Rheumatoid arthritis23 Sep 2016Within Guidelines
2016Merck Canada Inc.Zepatier 50/100 - 150 mg/tabletelbasvir / grazoprevir02451131Hepatitis C25 Jan 2016Subject to Investigation
2016Merck Canada Inc.Bridion - 100 mg/mLsugammadex02451816Selective Relaxant Binding Agent19 Feb 2016Subject to Investigation
2016Novartis Pharma Canada Inc.Afinitor - 7.5 mg/tableteverolimus02450267Cancer05 Apr 2016Does Not Trigger Investigation
2016Novartis Pharma Canada Inc.Signifor LAR - 20 mg/vialpasireotide02437252Acromegaly28 Jan 2016Within Guidelines
2016Novartis Pharma Canada Inc.Jadenu - 90 mg/tabletdeferasirox02452219Chronic iron overload24 Mar 2016Within Guidelines
2016Novartis Pharma Canada Inc.Jadenu - 180 mg/tabletdeferasirox02452227Chronic iron overload24 Mar 2016Within Guidelines
2016Novartis Pharma Canada Inc.Jadenu - 360 mg/tabletdeferasirox02452235Chronic iron overload24 Mar 2016Within Guidelines
2016Octapharma Canada Inc.Nuwiq - 250 unit/vialAntihemophilic factor (Recombinant, B-domain deleted), Antihemorrhagic Blood Coagulation Factor VIII02432951Hemophilia22 Dec 2015Within Guidelines
2016Octapharma Canada Inc.Nuwiq - 500 unit/vialAntihemophilic factor (Recombinant, B-domain deleted), Antihemorrhagic Blood Coagulation Factor VIII02432978Hemophilia22 Dec 2015Within Guidelines
2016Octapharma Canada Inc.Nuwiq - 2000 IU/VialAntihemophilic factor (Recombinant, B-domain deleted), Antihemorrhagic Blood Coagulation Factor VIII02432994Hemophilia14 Jul 2016Within Guidelines
2016Octapharma Canada Inc.Nuwiq - 1000 IU/VialAntihemophilic factor (Recombinant, B-domain deleted), Antihemorrhagic Blood Coagulation Factor VIII02432986Hemophilia21 Jul 2016Within Guidelines
2016Paladin Labs Inc.Iclusig - 45 mg/tabletponatinib02437341Cancer7 Jan 2016Within Guidelines
2016Pendopharm, Division of Pharmascience Inc.Vibativ - 750 mg/vialtelavancin hydrochloride02330725Antibiotic6 Jan 2016Subject to Investigation
2016Pfizer Canada Inc.Somavert - 25 mg/vialpegvisomant02448831Acromegaly10 Mar 2016Within Guidelines
2016Pfizer Canada Inc.Somavert - 30 mg/vialpegvisomant02448858Acromegaly10 Mar 2016Within Guidelines
2016Pfizer Canada Inc.Ibrance - 75 mg/capsulepalbociclib02453150Cancer20 Apr 2016Within Guidelines
2016Pfizer Canada Inc.Ibrance - 100 mg/capsulepalbociclib02453169Cancer19 Apr 2016Within Guidelines
2016Pfizer Canada Inc.Ibrance - 125 mg/capsulepalbociclib02453177Cancer19 Apr 2016Within Guidelines
2016PTC Therapeutics International LimitedTranslarna - 1,000 mg/pouchatalurenDuchenne muscular dystrophy8 Feb 2016Within Guidelines
2016Purdue PharmaBuTrans - 15 mg/patchbuprenorphine02450771Pain15 Jun 2016Does Not Trigger Investigation
2016Servier Canada Inc.Viacoram 3.5/2.5 - 6 mg/tabletperindopril arginine/amlodipine02451530Hypertension05 Apr 2016Within Guidelines
2016Servier Canada Inc.Viacoram 7/5 - 12 mg/tabletperindopril arginine/amlodipine02451557Hypertension05 Apr 2016Within Guidelines
2016Servier Canada Inc.Viacoram 14/10 - 24 mg/tabletperindopril arginine/amlodipine02451549Hypertension05 Apr 2016Within Guidelines
2016Takeda Canada Inc.Ninlaro - 2.3 mg/capsuleixazomib citrate02456796Cancer21 Sep 2016Within Guidelines
2016Takeda Canada Inc.Ninlaro - 3 mg/capsuleixazomib citrate02456818Cancer21 Sep 2016Within Guidelines
2016Takeda Canada Inc.Ninlaro - 4 mg/capsuleixazomib citrate02456826Cancer21 Sep 2016Within Guidelines
2016Teva Canada Innovation G.P.-S.E.N.CCopaxone - 40 mg/mLglatiramer acetate02456915Mutiple Sclerosis26 Aug 2016Does Not Trigger Investigation
2016UCB Canada Inc.Brivlera - 10 mg/tabletbrivaracetam02452936Epilepsy2 May 2016Within Guidelines
2016UCB Canada Inc.Brivlera - 25 mg/tabletbrivaracetam02452944Epilepsy2 May 2016Within Guidelines
2016UCB Canada Inc.Brivlera - 50 mg/tabletbrivaracetam02452952Epilepsy2 May 2016Within Guidelines
2016UCB Canada Inc.Brivlera - 75 mg/tabletbrivaracetam02452960Epilepsy2 May 2016Within Guidelines
2016UCB Canada Inc.Brivlera - 100 mg/tabletbrivaracetam02452979Epilepsy2 May 2016Within Guidelines
2016Vertex Pharmaceuticals Canada Inc.Orkambi 200/125 - 325 mg/tabletlumacaftor / ivacaftor02451379Cystic Fibrosis27 Jan 2016Does Not Trigger Investigation
2016ViiV Healthcare UlcTivicay - 50 mg/tabletdolutegravir02414945HIV8 Nov 2013 (Patented 26 Apr 2016)Subject to Investigation